Neuropathic Pain Therapeutics Summit

The First Industry-Dedicated Conference Focused on Accelerating Novel Neuropathic Pain Therapeutics into the Clinic.

The opioid crisis rages on unabated. Meanwhile, the global population continues to age, creating an enormous need for next-generation neuropathic pain treatment and management approaches. This has stimulated a renewed sense of urgency to discover, translate and accelerate non-addictive and clinically effective pain relief therapeutics into the clinic and to patients in pain.

As such, the Neuropathic Pain Therapeutics Digital Summit arrives as the first-ever industry dedicated meeting for large pharma, biotech and academia, to discover novel, non-addictive neuropathic pain therapeutic mechanisms of action.

Expect to be involved in interactive discussions on the diversity of next-generation neuropathic pain drugs in development including NaV1.7 channel inhibitors, antisense oligonucleotides, matrix metalloproteinase inhibitors, gene therapy, anti-TRPV1 antibody, cannabinoid-derived pharmaceutical, neuroimmune targeted, medical device approaches, and more!

This is your chance to understand the latest findings on the underlying pathophysiology of neuropathic pain. Overcome preclinical model challenges to identify pain biomarkers and harness the neuroimmune axis to tackle neuropathic pain and discuss novel pharmacological approaches along the neuropathic pain patient continuum of care.

Learn from 20+ thought leaders in our expert speaker faculty, access 18+ hours of content exploring the latest advances in the neuropathic pain therapy field and form meaningful connections during the multiple and varied hybrid networking sessions built into the event.

Join this industry-dedicated virtual forum as we unite drug developers and academics to tackle the most critical drug development challenges in accelerating novel neuropathic pain therapeutics into the clinic and to patients in need.

Group discounts and early booking rates are available. Please visit the website for full pricing information www.neuropathic-pain-therapeutics.com

Speakers: Steven Fox, Chairman & Founder, Akelos, Inc, Irving Sucholeiki, President & Chief Executive Officer, Aquilus Pharmaceuticals, Gary J. Bennett, Co-Founder, BioIntervene Inc., Richard Malamut, Chief Medical Officer & EVP, Collegium Pharmaceuticals, Lizandra Marcondes, Head of Medical Affairs US, Grunenthal/ Averitas, Patrick Sheets, Associate Professor of Pharmacology & Toxicity, Indiana University School of Medicine, Peter McNaughton, Professor of Pharmacology, King’s College London, Darrell A. Henze, Director – Neuroscience, Merck & Co., Inc., Fernando Aleman, Co-Founder & Chief Scientific Officer, Navega Therapeutics, Douglas E. Brenneman, Director of Pharmacology, Neuropathix, Inc., Joseph Foss, Chief Medical Officer, NeuroTherapia, Eric Grigsby, President & Chief Executive Officer, Neurovations, Smriti Iyengar, Director - Preclinical Screening Platform for Pain & Program Director, National Institute on Neurological Disorders & Stroke/ NIH, Daniela Papadia, Head of Discovery & Preclinical R&D - Ion Channel Targets in Pain, Oblique Therapeutics, Owen McManus, Chief Technology Officer, Q-State Biosciences, David Michelson, Chief Medical Officer, Regenacy Pharmaceuticals, Daniela Salvemini, Professor, St. Louis University School of Medicine, Sara Jane Ward, Assistant Professor of Pharmacology, Temple University Lewis Katz School of Medicine, Aurelia de Pauw, Sr Vice President, Clinical Programs / Medical Affairs, Tetra Bio-Pharma, Selwyn Jayakar, Instructor in Neurology, Woolf Lab, Boston Children’s Hospital, Stephen D. Collins, Chief Medical Officer, Xalud Therapeutics

Others Details

Brochure: https://go.evvnt.com/768538-0?pid=6581 Time: 8:00 am - 5:00 pm